Article Type
Article
Changed
Wed, 06/05/2024 - 12:33
Display Headline
Eosinophilic Gastrointestinal Diseases: Beyond EoE
Author(s)
Nirmala Gonsalves, MD, AGAF, FACG

Click here to view more from Gastroenterology Data Trends 2024

References
  1. Dellon ES, Gonsalves N, Abonia JP, et al. International consensus recommendations for eosinophilic gastrointestinal disease nomenclature. Clin Gastroenterol Hepatol. 2022;20(11):2474-2484.e3. doi:10.1016/j.cgh.2022.02.017
  2. Naramore S, Gupta SK. Nonesophageal eosinophilic gastrointestinal disorders: clinical care and future directions. J Pediatr Gastroenterol Nutr. 2018;67(3):318-321. doi:10.1097/MPG.0000000000002040
  3. Kinoshita Y, Sanuki T. Review of non-eosinophilic esophagitis-eosinophilic gastrointestinal disease (non-EoE-EGID) and a case series of twenty-eight affected patients. Biomolecules. 2023;13(9):1417. doi:10.3390/biom13091417
  4. Gonsalves N, Doerfler B, Zalewski A, et al. Prospective study of an amino acid-based elemental diet in an eosinophilic gastritis and gastroenteritis nutrition trial. J Allergy Clin Immunol. 2023;152(3):676-688. doi:10.1016/j.jaci.2023.05.024
  5. Oshima T. Biologic therapies targeting eosinophilic gastrointestinal diseases. Intern Med. 2023;62(23):3429-3430. doi:10.2169/internalmedicine.1911-23
  6. Pineton de Chambrun G, Gonzalez F, Canva JY, et al. Natural history of eosinophilic gastroenteritis. Clin Gastroenterol Hepatol. 2011;9(11):950-956.e1. doi:10.1016/j.cgh.2011.07.017
  7. Hirano I, Collins MH, King E, et al; CEGIR Investigators. Prospective endoscopic activity assessment for eosinophilic gastritis in a multi-site cohort. Am J Gastroenterol. 2022;117(3):413-423. doi:10.14309/ajg.0000000000001625
  8. Pesek RD, Reed CC, Muir AB, et al; Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). Increasing rates of diagnosis, substantial co-occurrence, and variable treatment patterns of eosinophilic gastritis, gastroenteritis, and colitis based on 10-year data across a multicenter consortium. Am J Gastroenterol. 2019;114(6):984-994. doi:10.14309/ajg.0000000000000228
Author and Disclosure Information

Nirmala Gonsalves, MD, AGAF, FACG
Professor of Medicine
Division of Gastroenterology & Hepatology
Northwestern University
Feinberg School of Medicine
Co-Director of Eosinophilic Gastrointestinal Disorders Program
Northwestern Memorial Hospital
Chicago, Illinois

Disclosures:
Serve(d) as a consultant for: AstraZeneca; Allakos; AbbVie; BMS; Sanofi-Regeneron
Serve(d) as a speaker or a member of a speakers bureau for: Sanofi-Regeneron

Publications
GI and Hepatology News
Topics
Upper GI Tract
Author(s)
Nirmala Gonsalves, MD, AGAF, FACG
Author(s)
Nirmala Gonsalves, MD, AGAF, FACG
Author and Disclosure Information

Nirmala Gonsalves, MD, AGAF, FACG
Professor of Medicine
Division of Gastroenterology & Hepatology
Northwestern University
Feinberg School of Medicine
Co-Director of Eosinophilic Gastrointestinal Disorders Program
Northwestern Memorial Hospital
Chicago, Illinois

Disclosures:
Serve(d) as a consultant for: AstraZeneca; Allakos; AbbVie; BMS; Sanofi-Regeneron
Serve(d) as a speaker or a member of a speakers bureau for: Sanofi-Regeneron

Author and Disclosure Information

Nirmala Gonsalves, MD, AGAF, FACG
Professor of Medicine
Division of Gastroenterology & Hepatology
Northwestern University
Feinberg School of Medicine
Co-Director of Eosinophilic Gastrointestinal Disorders Program
Northwestern Memorial Hospital
Chicago, Illinois

Disclosures:
Serve(d) as a consultant for: AstraZeneca; Allakos; AbbVie; BMS; Sanofi-Regeneron
Serve(d) as a speaker or a member of a speakers bureau for: Sanofi-Regeneron

Click here to view more from Gastroenterology Data Trends 2024

Click here to view more from Gastroenterology Data Trends 2024

References
  1. Dellon ES, Gonsalves N, Abonia JP, et al. International consensus recommendations for eosinophilic gastrointestinal disease nomenclature. Clin Gastroenterol Hepatol. 2022;20(11):2474-2484.e3. doi:10.1016/j.cgh.2022.02.017
  2. Naramore S, Gupta SK. Nonesophageal eosinophilic gastrointestinal disorders: clinical care and future directions. J Pediatr Gastroenterol Nutr. 2018;67(3):318-321. doi:10.1097/MPG.0000000000002040
  3. Kinoshita Y, Sanuki T. Review of non-eosinophilic esophagitis-eosinophilic gastrointestinal disease (non-EoE-EGID) and a case series of twenty-eight affected patients. Biomolecules. 2023;13(9):1417. doi:10.3390/biom13091417
  4. Gonsalves N, Doerfler B, Zalewski A, et al. Prospective study of an amino acid-based elemental diet in an eosinophilic gastritis and gastroenteritis nutrition trial. J Allergy Clin Immunol. 2023;152(3):676-688. doi:10.1016/j.jaci.2023.05.024
  5. Oshima T. Biologic therapies targeting eosinophilic gastrointestinal diseases. Intern Med. 2023;62(23):3429-3430. doi:10.2169/internalmedicine.1911-23
  6. Pineton de Chambrun G, Gonzalez F, Canva JY, et al. Natural history of eosinophilic gastroenteritis. Clin Gastroenterol Hepatol. 2011;9(11):950-956.e1. doi:10.1016/j.cgh.2011.07.017
  7. Hirano I, Collins MH, King E, et al; CEGIR Investigators. Prospective endoscopic activity assessment for eosinophilic gastritis in a multi-site cohort. Am J Gastroenterol. 2022;117(3):413-423. doi:10.14309/ajg.0000000000001625
  8. Pesek RD, Reed CC, Muir AB, et al; Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). Increasing rates of diagnosis, substantial co-occurrence, and variable treatment patterns of eosinophilic gastritis, gastroenteritis, and colitis based on 10-year data across a multicenter consortium. Am J Gastroenterol. 2019;114(6):984-994. doi:10.14309/ajg.0000000000000228
References
  1. Dellon ES, Gonsalves N, Abonia JP, et al. International consensus recommendations for eosinophilic gastrointestinal disease nomenclature. Clin Gastroenterol Hepatol. 2022;20(11):2474-2484.e3. doi:10.1016/j.cgh.2022.02.017
  2. Naramore S, Gupta SK. Nonesophageal eosinophilic gastrointestinal disorders: clinical care and future directions. J Pediatr Gastroenterol Nutr. 2018;67(3):318-321. doi:10.1097/MPG.0000000000002040
  3. Kinoshita Y, Sanuki T. Review of non-eosinophilic esophagitis-eosinophilic gastrointestinal disease (non-EoE-EGID) and a case series of twenty-eight affected patients. Biomolecules. 2023;13(9):1417. doi:10.3390/biom13091417
  4. Gonsalves N, Doerfler B, Zalewski A, et al. Prospective study of an amino acid-based elemental diet in an eosinophilic gastritis and gastroenteritis nutrition trial. J Allergy Clin Immunol. 2023;152(3):676-688. doi:10.1016/j.jaci.2023.05.024
  5. Oshima T. Biologic therapies targeting eosinophilic gastrointestinal diseases. Intern Med. 2023;62(23):3429-3430. doi:10.2169/internalmedicine.1911-23
  6. Pineton de Chambrun G, Gonzalez F, Canva JY, et al. Natural history of eosinophilic gastroenteritis. Clin Gastroenterol Hepatol. 2011;9(11):950-956.e1. doi:10.1016/j.cgh.2011.07.017
  7. Hirano I, Collins MH, King E, et al; CEGIR Investigators. Prospective endoscopic activity assessment for eosinophilic gastritis in a multi-site cohort. Am J Gastroenterol. 2022;117(3):413-423. doi:10.14309/ajg.0000000000001625
  8. Pesek RD, Reed CC, Muir AB, et al; Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). Increasing rates of diagnosis, substantial co-occurrence, and variable treatment patterns of eosinophilic gastritis, gastroenteritis, and colitis based on 10-year data across a multicenter consortium. Am J Gastroenterol. 2019;114(6):984-994. doi:10.14309/ajg.0000000000000228
Publications
GI and Hepatology News
Publications
GI and Hepatology News
Topics
Upper GI Tract
Article Type
Article
Display Headline
Eosinophilic Gastrointestinal Diseases: Beyond EoE
Display Headline
Eosinophilic Gastrointestinal Diseases: Beyond EoE
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Thu, 05/30/2024 - 09:45
Un-Gate On Date
Thu, 05/30/2024 - 09:45
Use ProPublica
CFC Schedule Remove Status
Thu, 05/30/2024 - 09:45
Hide sidebar & use full width
Do not render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Article Slideshow Optional Introduction

While great strides have been made in the last few decades to improve our understanding of the diagnosis and treatment of eosinophilic esophagitis (EoE), there is much to be learned about treating other non-EoE eosinophilic gastrointestinal diseases (EGIDs). One of the first challenges in diagnosing these rare conditions was developing a  consistent nomenclature. For instance, the term eosinophilic gastroenteritis was used previously as a blanket term for any type of eosinophilic gastrointestinal infiltration, but its varying uses and lack of consistency led to confusion with the diagnosis. To help improve clinical and research advances in disorders of eosinophils below the diaphragm, in 2022 an international committee convened to create a consensus on standardizing EGID nomenclature. This important milestone created an EGID nomenclature system to specify the location of inflammation in a more precise and defined way.1 Additional challenges with diagnosing and managing the non-EoE EGIDs include the heterogenous symptom presentation, which can lead to delay in diagnosis. Furthermore, the lack of an FDA-approved treatment for non-EoE EGIDs creates additional hurdles for treatment.

Slide
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Slide Media